Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7130171 | 0.98 | TSHR (0.67) | TSHRALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL70342 | 0.90 | TSHR (0.66) | TSHRALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL5592685 | 0.86 | MAPT (0.63) | ALDH1A1L3MBTL1MAPTGAASMN1; SMN2 | |
| SCHEMBL8142603 | 0.86 | TSHR (0.73) | TSHRALDH1A1MAPTGAAPKM | |
| SCHEMBL7821728 | 0.85 | TSHR (0.77) | TSHRALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL22363340 | 0.84 | TSHR (0.51) | TSHRALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL3067050 | 0.83 | HPGD (0.66) | ALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL28855893 | 0.83 | ALDH1A1 (0.70) | ALDH1A1HPGD | |
| SCHEMBL26998806 | 0.83 | HPGD (0.59) | TSHRALDH1A1L3MBTL1MAPK1HSD17B10 | |
| SCHEMBL307601 | 0.83 | MAPT (0.59) | ALDH1A1L3MBTL1MAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693531-A | Synthesis method of bridged polycyclic lactam compound | 河南师范大学 | 2023-09-05 | — | — | CN | claimed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2023-11-07 | — | — | US | disclosed |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2023-11-07 | — | — | US | disclosed |
| CN-116693531-A | Synthesis method of bridged polycyclic lactam compound | 河南师范大学 | 2023-09-05 | — | — | CN | disclosed |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | WELLMARKER BIO CO., LTD. (KR) | 2022-09-20 | — | — | US | disclosed |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO, LTD. (KR) | 2022-09-15 | — | — | US | disclosed |
| CN-111295386-B | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-113121435-B | Synthetic method of 2, 4-dichloroquinoline compound | 辽宁大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-1982978-A1 | PYRIDONE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-0449346-B1 | 4-Piperidinyl-ergoline derivatives | PHARMACIA SPA (IT) | 1995-05-10 | — | — | EP | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| EP-0449346-A2 | 4-Piperidinyl-ergoline derivatives | PHARMACIA S.p.A. (IT) | 1991-10-02 | — | — | EP | disclosed |
| US-4738971-A | ENHANCED CELL-MEDIATED IMMUNITY; ANTIARTHRITIC AGENTS; NONTOXIC | AKTIEBOLASET LEO (SE) | 1988-04-19 | — | — | US | disclosed |
| US-4736056-A | Process for the production of malonic acid derivative compounds | UNION CARBIDE AGRICULTURAL PRODUCTS COMPANY, INC., T.W. ALEXANDER DR., RESEARCH TRIANGLE PARK, NC. A CORP. OF PA. | 1988-04-05 | — | — | US | disclosed |
| US-4547511-A | FOR ENHANCIN CELL-MEDIATED IMMUNITY | AKTIEBOLAGET LEO (SE) | 1985-10-15 | — | — | US | disclosed |
| EP-0059698-B1 | HETEROCYCLIC CARBOXAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND METHODS OF TREATMENT THEREWITH | AB LEO (SE) | 1985-09-25 | — | — | EP | disclosed |
| US-4407797-A | ANTIULCER AGENT | RHONE-POULENC SANTE (FR) | 1983-10-04 | — | — | US | disclosed |
| EP-0059698-A1 | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith | AB LEO (SE) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | MAP4K5, MAP4K2, MAP3K9 | TSHR 1782/4885ALDH1A1 2254/4885L3MBTL1 4523/4885 |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, POLA1, POLR2B | TSHR 4253/4885ALDH1A1 2997/4885L3MBTL1 3525/4885 |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, TOP2A, POLI | TSHR 4059/4885ALDH1A1 3656/4885L3MBTL1 3460/4885 |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PRKACA, MAP4K5, MAPKAPK5 | TSHR 2315/4885ALDH1A1 2359/4885L3MBTL1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.